AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22930766 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic restorations
Number of subjects: 37
Study 20442543 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (n=16)
Number of subjects: 45
Study 20442543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (n=14)
Number of subjects: 45
Study 20442543 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (n=15)
Number of subjects: 45
Study 18630487 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative immunotherapy with IL-2 (12 MIU/day SC for 3 consecutive days)
Number of subjects: 30
Study 18630487 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 30
Study 18630487 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative immunotherapy with IL-2 plus surgery
Number of subjects: 30
Study 16052765 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop/Z100 (3M ESPE)
Number of subjects: 200
Study 16052765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian One-Step Plus/AeliteFil (Bisco)
Number of subjects: 200
Study 16052765 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus SE/Prodigy (SDS Kerr)
Number of subjects: 200
Study 16052765 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III/TPH (Dentsply Caulk)
Number of subjects: 200
Study 16052765 — intervention group
Group type: COMPARATOR
Intervention: Control: Prime&Bond NT/TPH (Dentsply Caulk)
Number of subjects: 200
Study 16052765 — intervention group
Group type: COMPARATOR
Intervention: Control: Z100
Number of subjects: 200
Study 12193491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 50 micro g and morphine 500 micro g
Number of subjects: 24
Study 10063812 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (C: 25 g X d(‐1) for 5 d)
Number of subjects: 9
Study 10063812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9
Study 7734252 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine alone (0.2 mg kg‐1 bolus followed by 0.5 mg kg‐1 h‐1 infusion)
Number of subjects: 30
Study 7734252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine and colloid (polygeline, Haemaccel) 8 ml kg‐1
Number of subjects: 30
Study 1791077 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with cefotaxime
Number of subjects: 588
Study 7059416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prorenoate potassium
Number of subjects: 12
Study 7059416 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 12
Study 7059416 — intervention group
Group type: EXPERIMENTAL
Intervention: Both compounds
Number of subjects: 12
Study 31245333 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe with attached angiocath tubing
Number of subjects: 38
Study 31245333 — intervention group
Group type: EXPERIMENTAL
Intervention: Elephant Ear Washer Bottle System®
Number of subjects: 38
Study 31245333 — intervention group
Group type: EXPERIMENTAL
Intervention: OtoClear® Spray Wash Kit
Number of subjects: 38
Study 31245333 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal curette
Number of subjects: 38
Study 31245333 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall procedures
Number of subjects: 38
Study 28119083 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (2×200mg)
Number of subjects: 39
Study 28119083 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (2×20mg)
Number of subjects: 39
Study 28119083 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2×200mg)
Number of subjects: 39
Study 28119083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 27029801 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART)
Number of subjects: 124
Study 27029801 — intervention group
Group type: COMPARATOR
Intervention: Hall Technique (HT)
Number of subjects: 124
Study 25007392 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 2044
Study 25007392 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 2044
Study 25007392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2044
Study 25007392 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg
Number of subjects: 2044
Study 25007392 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 2044
Study 22219027 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure to a single direction of motion
Number of subjects: 0
Study 22219027 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysically measured adaptation tuning curves
Number of subjects: 0
Study 19291114 — intervention group
Group type: EXPERIMENTAL
Intervention: Maggot debridement therapy (MDT) with Lucilia cuprina
Number of subjects: 29
Study 19291114 — intervention group
Group type: COMPARATOR
Intervention: Conventional debridement
Number of subjects: 29
Study 16784318 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered self-expanding stent
Number of subjects: 14
Study 16784318 — intervention group
Group type: COMPARATOR
Intervention: Bare self-expanding stent
Number of subjects: 14
Study 14735048 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (Duraflo II)
Number of subjects: 30
Study 14735048 — intervention group
Group type: COMPARATOR
Intervention: Non-coated circuit (control)
Number of subjects: 30
Study 10889289 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐rTMS of the LPFC (real stimulation)
Number of subjects: 25
Study 10889289 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation of the LPFC
Number of subjects: 25
Study 8865378 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS applied over the second intercostal spaces during inspiration
Number of subjects: 11
Study 8865378 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS applied over the second intercostal spaces during expiration
Number of subjects: 11
Study 8865378 — intervention group
Group type: COMPARATOR
Intervention: TENS applied over the deltoid muscles during inspiration (control)
Number of subjects: 11
Study 8865378 — intervention group
Group type: COMPARATOR
Intervention: No TENS applied (fourth occasion)
Number of subjects: 11
Study 1633839 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection of glucagon (1 mg)
Number of subjects: 6
Study 1633839 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon injection with CGRP (10 nmole)
Number of subjects: 6
Study 1633839 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon injection using a multihole 'sprinkler' needle
Number of subjects: 6
Study 6405428 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous d-amphetamine sulphate (15 mg)
Number of subjects: 0
Study 6405428 — intervention group
Group type: COMPARATOR
Intervention: Oral d-amphetamine sulphate (15 mg)
Number of subjects: 0
Study 31492766 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ppm of EGF ointment
Number of subjects: 80
Study 31492766 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ppm of EGF ointment
Number of subjects: 80
Study 31492766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31492766 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF arms (1 ppm and 20 ppm)
Number of subjects: 80
Study 31175209 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex (DLPFC) with 10 Hz stimulation for 10 sessions.
Number of subjects: 30
Study 31175209 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (control group).
Number of subjects: 30
Study 28079557 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (20 μg kg‐1 min‐1)
Number of subjects: 24
Study 28079557 — intervention group
Group type: COMPARATOR
Intervention: Control (no dobutamine)
Number of subjects: 24
Study 25500486 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor tablets administered orally
Number of subjects: 36
Study 25500486 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor tablets administered via nasogastric tube
Number of subjects: 36
Study 25500486 — intervention group
Group type: COMPARATOR
Intervention: Whole ticagrelor tablets administered orally
Number of subjects: 36
Study 25500486 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor tablets (both methods)
Number of subjects: 36
Study 23421629 — intervention group
Group type: COMPARATOR
Intervention: Gluma Desensitizer (Heraeus Kulzer)
Number of subjects: 30
Study 23421629 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG Laser (Power Laser™ ST6, Lares Research®)
Number of subjects: 30
Study 23421629 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG Laser + Gluma Desensitizer
Number of subjects: 30
Study 21551475 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR (rate responsive pacing)
Number of subjects: 13
Study 21551475 — intervention group
Group type: COMPARATOR
Intervention: DDD (control)
Number of subjects: 13
Study 19660002 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 200 mg oral dose under fasting conditions
Number of subjects: 15
Study 19660002 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 200 mg oral dose after a low-fat meal
Number of subjects: 15
Study 19660002 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 200 mg oral dose after a high-fat meal
Number of subjects: 15
Study 16537872 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 10
Study 16537872 — intervention group
Group type: COMPARATOR
Intervention: Standard chest physiotherapy (SCPT)
Number of subjects: 10
Study 16537872 — intervention group
Group type: EXPERIMENTAL
Intervention: HFCWO
Number of subjects: 10
Study 16537872 — intervention group
Group type: COMPARATOR
Intervention: SCPT
Number of subjects: 10
Study 15462701 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbicort adjustable maintenance dosing plan (SAMD) - budesonide/formoterol 1-4 inhalations twice daily depending on symptoms
Number of subjects: 1553
Study 15462701 — intervention group
Group type: COMPARATOR
Intervention: Symbicort fixed dosing - 2 inhalations twice daily
Number of subjects: 1553
Study 15462701 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMD
Number of subjects: 1553
Study 15462701 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosing
Number of subjects: 1553
Study 11477028 — intervention group
Group type: EXPERIMENTAL
Intervention: Powerlifters
Number of subjects: 45
Study 11477028 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 45
Study 9757853 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (13 mg/m2 every morning and 3 mg/m2 every afternoon for approximately 12 weeks)
Number of subjects: 70
Study 9757853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9757853 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 70
Study 7818065 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with intravenous pethidine
Number of subjects: 200
Study 7818065 — intervention group
Group type: COMPARATOR
Intervention: Nurse-controlled pethidine infusions
Number of subjects: 200
Study 2967622 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg Zoladex
Number of subjects: 90
Study 2967622 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg Zoladex
Number of subjects: 90
Study 2967622 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mg Zoladex
Number of subjects: 90
Study 29544738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (100 mg for ages 2-11, 200 mg for ages 12-17)
Number of subjects: 16
Study 29544738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 26111163 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter condition
Number of subjects: 115
Study 26111163 — intervention group
Group type: COMPARATOR
Intervention: No-letter condition
Number of subjects: 115
Study 26354560 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Volume Monitoring (BVM) treatment
Number of subjects: 14
Study 26354560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BVM treatment)
Number of subjects: 14
Study 22527264 — intervention group
Group type: EXPERIMENTAL
Intervention: Human rights‐based intervention approach with four dialogical meetings focused on medication intake scenes
Number of subjects: 121
Study 22527264 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 121
Study 22527264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG)
Number of subjects: 121
Study 20184444 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of paracetamol
Number of subjects: 90
Study 20184444 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of lornoxicam
Number of subjects: 90
Study 20184444 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of tramadol
Number of subjects: 90
Study 19032138 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (salmeterol/fluticasone propionate) 50/250 microg bd or 50/500 microg bd via Diskus
Number of subjects: 424
Study 19032138 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (salmeterol/fluticasone propionate)
Number of subjects: 424
Study 19032138 — intervention group
Group type: COMPARATOR
Intervention: CC (current care)
Number of subjects: 424
Study 17157780 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytrex (oxycodone + ultralow-dose naltrexone) bid
Number of subjects: 719
Study 17157780 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone qid
Number of subjects: 719
Study 12728375 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofile, heavy-weight, rigid mesh (group A)
Number of subjects: 40
Study 12728375 — intervention group
Group type: COMPARATOR
Intervention: Smooth, heavy-weight variant of polypropylene mesh (group B)
Number of subjects: 40
Study 10681282 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato chips containing 40 g of olestra per day
Number of subjects: 10
Study 10681282 — intervention group
Group type: COMPARATOR
Intervention: Conventional potato chips (control)
Number of subjects: 10
Study 9148019 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DR expression on bile ducts in advanced primary biliary cirrhosis
Number of subjects: 31
Study 9148019 — intervention group
Group type: EXPERIMENTAL
Intervention: B7-2 expression on bile ducts in advanced primary biliary cirrhosis
Number of subjects: 31
Study 9148019 — intervention group
Group type: EXPERIMENTAL
Intervention: B7-1 expression on bile ducts in advanced primary biliary cirrhosis
Number of subjects: 31
Study 9148019 — intervention group
Group type: EXPERIMENTAL
Intervention: B7-1 and B7-2 expression on bile ducts in early primary biliary cirrhosis
Number of subjects: 31
Study 9148019 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DR, B7-1, and B7-2 expression on professional antigen presenting cells
Number of subjects: 31
Study 9148019 — intervention group
Group type: COMPARATOR
Intervention: Co-expression of B7-1 and B7-2 on HLA-DR+ bile ducts in autoimmune hepatitis
Number of subjects: 31
Study 8436635 — intervention group
Group type: EXPERIMENTAL
Intervention: F2 (2500 alternations per minute)
Number of subjects: 0
Study 8436635 — intervention group
Group type: COMPARATOR
Intervention: F1 (2100 alternations per minute)
Number of subjects: 0
Study 8436635 — intervention group
Group type: COMPARATOR
Intervention: F3 (3500 alternations per minute)
Number of subjects: 0
Study 3301923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream once daily
Number of subjects: 62
Study 3301923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream twice daily
Number of subjects: 62
Study 29534134 — intervention group
Group type: COMPARATOR
Intervention: Tissue-level implants restored with platform matching (control group)
Number of subjects: 100
Study 29534134 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-level implants restored with platform switching (test group)
Number of subjects: 100
Study 29534134 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between both groups
Number of subjects: 100
Study 26334577 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic PVT (IPVT)
Number of subjects: 79
Study 26334577 — intervention group
Group type: EXPERIMENTAL
Intervention: SPVT
Number of subjects: 79
Study 26334577 — intervention group
Group type: COMPARATOR
Intervention: Control group (C-IPVT)
Number of subjects: 79
Study 26334577 — intervention group
Group type: EXPERIMENTAL
Intervention: IPVT
Number of subjects: 79
Study 26334577 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference increase
Number of subjects: 79
Study 25201794 — intervention group
Group type: EXPERIMENTAL
Intervention: SSI reduction bundle (prohibition of razors, chlorhexidine-alcohol use, correct timing of prophylactic antibiotics)
Number of subjects: 8
Study 25201794 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct timing of preoperative prophylactic antibiotics
Number of subjects: 8
Study 25201794 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of 0 SSIs per center
Number of subjects: 8
Study 24712192 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar plate
Number of subjects: 69
Study 24712192 — intervention group
Group type: COMPARATOR
Intervention: External fixator
Number of subjects: 69
Study 19349870 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir monotherapy
Number of subjects: 198
Study 19349870 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (lopinavir-ritonavir and 2 nucleosides)
Number of subjects: 198
Study 17224426 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel catheter for simultaneous angiography of ipsilateral pulmonary veins
Number of subjects: 0
Study 16025024 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARITE artificial disc
Number of subjects: 304
Study 16025024 — intervention group
Group type: COMPARATOR
Intervention: Anterior lumbar interbody fusion
Number of subjects: 304
Study 12399672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (potent topical steroids + 20% azelaic acid cream)
Number of subjects: 30
Study 12399672 — intervention group
Group type: COMPARATOR
Intervention: 20% azelaic acid cream monotherapy
Number of subjects: 30
Study 18653145 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Number of subjects: 74
Study 18653145 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled physical exercise
Number of subjects: 74
Study 18653145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of caloric restriction and physical exercise with pharmacological treatment
Number of subjects: 74
Study 7660761 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐h blood glucose value of 8.0 to 8.9 mmol/l
Number of subjects: 223
Study 7660761 — intervention group
Group type: COMPARATOR
Intervention: Control group (2‐h blood glucose value < 8.0 mmol/l)
Number of subjects: 223
Study 2178992 — intervention group
Group type: EXPERIMENTAL
Intervention: Femodene
Number of subjects: 456
Study 2178992 — intervention group
Group type: COMPARATOR
Intervention: Microgynon-30
Number of subjects: 456
Study 327948 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium 169 injection (+prednisolone acetate)
Number of subjects: 36
Study 327948 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (+prednisolone acetate)
Number of subjects: 36
Study 31081712 — intervention group
Group type: EXPERIMENTAL
Intervention: Er;Cr:YSGG laser treatment at 3.75 W power and 15 Hz frequency for 4 min
Number of subjects: 110
Study 31081712 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 110
Study 31081712 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofluoric (HF) acid treatment
Number of subjects: 110
Study 31081712 — intervention group
Group type: EXPERIMENTAL
Intervention: L1S treatment
Number of subjects: 110
Study 31081712 — intervention group
Group type: EXPERIMENTAL
Intervention: L2D treatment
Number of subjects: 110
Study 31081712 — intervention group
Group type: EXPERIMENTAL
Intervention: L1D treatment
Number of subjects: 110
Study 31081712 — intervention group
Group type: EXPERIMENTAL
Intervention: L2S treatment
Number of subjects: 110
Study 25985392 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years parenting intervention
Number of subjects: 154
Study 25985392 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 154
Study 26407357 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal protective equipment (PPE) use when caring for patients with suspected pertussis
Number of subjects: 343
Study 26407357 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal protective equipment (PPE) use for patients with any respiratory symptoms
Number of subjects: 343
Study 26407357 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes toward PPE
Number of subjects: 343
Study 26407357 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and skills regarding PPE
Number of subjects: 343
Study 26407357 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived barriers to PPE use
Number of subjects: 343
Study 26407357 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of PPE use as a norm
Number of subjects: 343
Study 26407357 — intervention group
Group type: COMPARATOR
Intervention: Perceived infection risk or mask accessibility
Number of subjects: 343
Study 23234638 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial physical therapy
Number of subjects: 48
Study 23234638 — intervention group
Group type: COMPARATOR
Intervention: Global therapeutic massage
Number of subjects: 48
Study 21690592 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP measurements using a monitor that transmitted measurements electronically
Number of subjects: 444
Study 21690592 — intervention group
Group type: COMPARATOR
Intervention: Clinic BP measurements obtained during outpatient visits
Number of subjects: 444
Study 21690592 — intervention group
Group type: COMPARATOR
Intervention: Standardized research BP measurements at 6‐month intervals
Number of subjects: 444
Study 19506377 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsafe injecting practices (receptive syringe sharing after an HIV‐infected IDU)
Number of subjects: 446
Study 19506377 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsafe injecting practices (distributive syringe sharing)
Number of subjects: 446
Study 19506377 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsafe injecting practices (sharing cookers)
Number of subjects: 446